D. Boral Capital reissued their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $30.00 target price on the stock.
Several other equities research analysts also recently weighed in on the company. EF Hutton Acquisition Co. I upgraded ImmunityBio to a “strong-buy” rating in a report on Wednesday, October 23rd. BTIG Research started coverage on shares of ImmunityBio in a research note on Friday, January 10th. They set a “buy” rating and a $6.00 target price for the company.
Get Our Latest Research Report on ImmunityBio
ImmunityBio Trading Down 1.3 %
Institutional Investors Weigh In On ImmunityBio
Hedge funds have recently modified their holdings of the business. State Street Corp boosted its position in ImmunityBio by 10.1% during the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company’s stock valued at $32,195,000 after acquiring an additional 790,408 shares in the last quarter. Barclays PLC boosted its holdings in shares of ImmunityBio by 127.4% in the 3rd quarter. Barclays PLC now owns 361,036 shares of the company’s stock valued at $1,344,000 after buying an additional 202,248 shares in the last quarter. HighTower Advisors LLC bought a new position in shares of ImmunityBio during the 3rd quarter worth approximately $136,000. Mirae Asset Global Investments Co. Ltd. lifted its position in ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after acquiring an additional 4,545 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in ImmunityBio in the third quarter worth $143,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.
About ImmunityBio
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Featured Articles
- Five stocks we like better than ImmunityBio
- Roth IRA Calculator: Calculate Your Potential Returns
- Sizing Up a New Opportunity for NVIDIA Investors
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- ETF Screener: Uses and Step-by-Step Guide
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.